

Table 2. Response to 1st induction therapy in patients with or without aberrant expression of *MIR9*

	<i>MIR9</i> (+)	<i>MIR9</i> (-)	<i>P</i>
1st induction therapy	(n=6)	(n=26)	
L-Asp+ATC+VCR+PSL(±CPA)	4	11	
Hyper CVAD	2	10	0.406
Imatinib+Hyepr CVAD	0	5	
response to 1st induction therapy	(n=6)	(n=26)	
CR	4	21	
Non-CR	2	5	0.451
response to 1st induction therapy in T-ALL	(n=3)	(n=4)	
CR	2	3	
Non-CR	1	1	0.809
response to 1st induction therapy in B-ALL	(n=3)	(n=22)	
CR	2	18	
Non-CR	1	4	0.538
response to 1st induction therapy in Ph1(+) ALL	(n=2)	(n=11)	
CR	1	8	
Non-CR	1	3	0.522
response to 1st induction therapy in Ph1(-) ALL	(n=4)	(n=15)	
CR	3	13	
Non-CR	1	2	0.57